CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Feb 11, 2021

CTI BioPharma宣布根据纳斯达克上市规则第5635条授予诱因-2021年2月11日

2021-02-11 21:03:34 BioSpace

本文共734个字,阅读需2分钟

CTI BioPharma Corp. today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees with a grant date of February 10, 2021, as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan and material to the employees' acceptance of employment with the company. The equity awards were approved on February 10, 2021, in accordance with Nasdaq Listing Rule 5635. The employees received options to purchase an aggregate of 160,000 shares of CTI BioPharma common stock. The options have an exercise price of $3.45, which is equal to the closing price of CTI BioPharma common stock on February 10, 2021, the grant date of the awards. One-fourth of the options will vest on each anniversary of the employee's date of hire, subject to the employee's continued employment with CTI BioPharma on such vesting dates. The options have a ten-year term. About CTI BioPharma Corp. We are a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. We concentrate our efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, we are focused on evaluating pacritinib, our sole product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis. In addition, we have recently started developing pacritinib for use in hospitalized patients with severe COVID-19, in response to the COVID-19 pandemic. We are headquartered in Seattle, Washington. CTI BioPharma Investor Contacts: Maeve Conneighton/Maghan Meyers +212-600-1902 cti@argotpartners.com multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-301226569.html
CTI BioPharma Corp.今日宣布,其董事会薪酬委员会授予两名新员工股权奖励,授予日期为2021年2月10日,作为本公司经修订及重述的2017年股权激励计划之外的股权诱因奖励,以及该等员工接受本公司聘用的材料。股权奖励已于2021年2月10日根据纳斯达克上市规则5635获得批准。 员工获得了购买总计160,000股CTI BioPharma普通股的期权。期权的行权价格为3.45美元,与奖励授予日2021年2月10日CTI生物制药普通股的收盘价相等。四分之一的选择权将于雇员受雇日的每个周年日归属,但须视雇员于该归属日继续受雇于CTI BioPharma而定。期权的期限为十年。 CTI生物制药公司简介。 我们是一家生物制药公司,专注于血液相关癌症的新型靶向疗法的获取、开发和商业化,为患者及其医疗保健提供者提供独特的益处。我们的努力集中在针对血液相关癌症的治疗上,因为那里的医疗需求尚未得到满足。特别是,我们专注于评估帕克里替尼,我们唯一的候选产品,目前处于积极的后期开发阶段,用于治疗成人骨髓纤维化患者。此外,我们最近开始研发帕克里替尼,用于住院重症新冠患者,以应对新冠大流行。我们的总部设在华盛顿州西雅图。 CTI生物制药投资者联系人: Maeve Conneighton/Maghan Meyers +212-600-1902 cti@argotpartners.com 多媒体:http://www.prnewswire.com/news-releases/cti-biopharma-announces-incurement-grants-under-nasdaq-listing-rule-5635c4-301226569.html

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文